Benzodiazepines and older people by Gauci, Marise
Benzodiazepines and 
older people 
by Marise Gauci B.Pharm.(Hons.) MSc 
- - ----I Clinical Pharmacist 
Zammit Clapp Hospital 
There is a high prevalence of benzodiazepine use among elderly persons despite the fact that this 
sector of the population is particularly susceptible to the adverse effects of these medicines. Short 
half-life benzodiazepines are usually preferred for chronic use in older adults because they do not 
accumulate in the body, although they have a higher potential for dependence and are more strongly 
associated with withdrawal symptoms. A review of the literature confirms that benzodiazepines should 
be prescribed with caution, at low doses andfor short periods. 
Benzodiazepines are often prescribed for elderly patients 
as hypnotics and anxiolytics. Several problems associated 
with benzodiazepine use in this patient population are well 
documented and therefore the topic merits particular 
attention. 
Key concerns 
With advancing age, elderly persons are more sensitive 
to the potential side effects of benzodiazepines because 
of altereu phaImacok.inetics anu phallllacouYllamics. 
Numerous studies of benzodiazepine kinetics have been 
conducted and have shown that alterations in the 
distribution and elimination of these agents occur among 
older patients. Benzodiazepines with longer half-lives, 
such as chlordiazepoxide, diazepam, and flurazepam, 
are more likely to accumulate in the body and cause 
prolonged sedation. l Furthermore, alterations in 
pharmacodynamics among elderly patients can be more 
important in explaining the altered response to 
benzodiazepines. The increased sensitivity of older people 
to benzodiazepines is due to age-related alterations in 
the central nervous system receptors .2 
The use of benzodiazepines among elderly patients has 
been associated with intellectual and cognitive 
impairment. Cognitive impairment is characterized by 
anterograde amnesia, diminished short-term recall and 
increased forgetfulness . These symptoms are consistent 
with the early stages of dementia and can lead to a false 
diagnosis. Cognitive impairment seems to develop 
insidiously as a late complication of benzodiazepine use 
and is most commonly associated with long-acting 
benzodiazepines. Elderly patients with cognitive 
impairment show improved functioning once the drug 
has been discontinued. 3 
Benzodiazepines may contribute to psychomotor 
impairment and increase the risk of falls and automobile 
accidents . Psychomotor impairment is characterized by 
slowed reaction time and diminished speed and accuracy 
of motor tasks. Several studies show evidence of an increased 
risk of hip fracture and recurrent falls among elderly patients 
taking benzodiazepines. The risk of falls has been associated 
with sudden increases in dosage and with continuous use 
of benzodiazepines.4 
Benzodiazepine dependence is a serious problem among 
elderly persons. Factors potentially associated with an 
increased risk of developing dependency include long-
term use, short duration of action, high dose, high potency, 
alcohol or other drug dependency and personality 
disorders. 5 
Appropriate prescribing 
It is generally advised that, if benzodiazepines are used 
in the elderly, they should be prescribed half the 
recommended dose of adults. Benzodiazepines used as 
hypnotics include nitrazepam which has a prolonged action 
and may give rise to residual effects the following day, with 
repeated doses tending to be cumulative. More appropriate 
options are lormetazepam and temazepam which act for a 
shorter time and have little or no hangover effect. Alternative 
hypnotics are the Z drugs e.g. zolpidem which are non-
benzodiazepine hypnotics, but act on the benzodiazepine 
receptors. The Z drugs were developed with the aim of 
overcoming some of the disadvantages of benzodiazepines 
but available evidence has not clearly shown these benefits. 
In fact NICE guidance on the use of Z drugs recommends 
that because of the lack of evidence to distinguish between 
these agents and the short-acting benzodiazepine hypnotics, 
the drug with the lower purchase cost for the patient should 
be prescribed. 6 
Benzodiazepines can be effective in alleviating anxiety 
states. Although these drugs are often prescribed to patients 
with stress-related symptoms, unhappiness or physical 
disease, their use in many situations is unjustified. In 
particular, they are not appropriate for treating depression 
or chronic psychosis.7 All benzodiazepines work well in 
anxiety, however, elderly people respond better and 
experience fewer adverse effects with short or intermediate-
acting agents such as lorazepam than with longer acting 
ones such as diazepam. Occasionally, short-acting agents 
produce a rebound anxiety effect before the next dose is 
given. In such cases, a longer acting drug may be preferred.s 
Reducing use 
Benzodiazepine treatment should be limited to the lowest 
possible dose for the shortest possible time. Stopping the 
drug is easier if clinicians and pharmacists clarify from the 
outset that treatment is only for a brief definite period. After 
continuous use for an extended time, benzodiazepines may 
be difficult to stop because of psychological and physical 
reasons. Nevertheless, periodic efforts should be made to 
stop the drug or at least reduce the dose. Withdrawal should 
be gradual because abrupt withdrawal may produce 
confusion, toxic psychosis, convulsions or a condition 
resembling delirium tremens. Abrupt discontinuation of 
short-acting benzodiazepines may produce a more severe 
withdrawal than long-acting agents.9 
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:SVITIot:OITlHIlaV develop at any time up to 3 weeks after 
a long-acting benzodiazepine, but may occur within 
a in the case of a short -acting one. The British 
National Formulary includes a suggested withdrawal protocol 
involving transfer to an equivalent dose of diazepam and slowly 
reducing the dose. This may help those patients who experience 
symptoms when reducing their intake of original 
benzodiazepine.7 Gradual tapering of benzodiazepines has 
been shown to be at least as effective among elderly patients 
as among younger patients. Schweizer and colleagues1o 
compared the severity of withdrawal symptoms and clinical 
outcomes in a matched sample of elderly and young patients. 
The elderly patients showed significantly less severe withdrawal 
symptoms dUling a gradual taper and did equally well in terms 
of outcomes as their younger counterparts. The authors 
speculated that a slower clearance of the medication may 
attenuate withdrawal symptoms and that diminished neuronal 
capacity among elderly persons causes less rebound overactivity. 
Conclusion 
When prescribing benzodiazepines for older people, 
careful consideration should be given to minimizing doses 
and duration of treatment. Medication reviews are 
particularly important in this sector of the population when 
decreasing doses or discontinuing drugs which are no 
longer appropriate for the patient. Moreover, effective 
communication with the patient and carers is imperative 
since resistance to withdrawing these agents is often 
encountered. 8J 
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